Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PD-217,014 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| To characterise the effectiveness of PD-217,014 in the treatment of chronic pain. A numerical pain intensity rating scale is used to assess pain and a mean endpoint (week 4) pain score change from baseline is calculated. |
| Measure | Description | Time Frame |
|---|---|---|
| - Assess the effect of PD-217,014 on responder rate based on the primary endpoint, mean endpoint sleep interference score and the SF-McGill questionnaire (change from baseline to week 4) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Warrawong | New South Wales | Australia | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Westmead |
| New South Wales |
| Australia |
| Pfizer Investigational Site | Kippa-Ring | Queensland | Australia |
| Pfizer Investigational Site | Maroochydore | Queensland | Australia |
| Pfizer Investigational Site | Bedford Park | South Australia | Australia |
| Pfizer Investigational Site | Perth | Western Australia | Australia |
| Pfizer Investigational Site | Woodville | Australia |
| Pfizer Investigational Site | Kelowna | British Columbia | Canada |
| Pfizer Investigational Site | Halifax | Nova Scotia | Canada |
| Pfizer Investigational Site | Toronto | Ontario | Canada |
| Pfizer Investigational Site | Sherbrooke | Quebec | Canada |
| Pfizer Investigational Site | Ste-foy | Quebec | Canada |
| Pfizer Investigational Site | Brno | Czechia |
| Pfizer Investigational Site | CZ-Praha 8 | Czechia |
| Pfizer Investigational Site | České Budějovice | Czechia |
| Pfizer Investigational Site | Pilsen | Czechia |
| Pfizer Investigational Site | Prague | Czechia |
| Pfizer Investigational Site | Arnhem | Netherlands |
| Pfizer Investigational Site | Breda | Netherlands |
| Pfizer Investigational Site | Kampen | Netherlands |
| Pfizer Investigational Site | Roosendaal | Netherlands |
| Pfizer Investigational Site | Rotterdam | Netherlands |
| Pfizer Investigational Site | Stadskanaal | Netherlands |
| Pfizer Investigational Site | Granada | Granada | Spain |
| Pfizer Investigational Site | Madrid | Madrid | Spain |
| Pfizer Investigational Site | Málaga | MALAGA | Spain |
| Pfizer Investigational Site | Seville | SEVILLA | Spain |
| Pfizer Investigational Site | Barcelona | Spain |
| Pfizer Investigational Site | Portsmouth | Hants | United Kingdom |
| Pfizer Investigational Site | Northampton | Northants | United Kingdom |
| Pfizer Investigational Site | London | United Kingdom |
| Pfizer Investigational Site |
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided